Foreword, PharManufacturing



August 28, 2007


Never has there been a more exciting time to be working with peptides. The compilation of thought-provoking articles from the industry’s leading solution providers in this inaugural issue of PharManufacturing conveys a renewed focus on peptides and their potential.

All segments of the global peptide market are thriving, from therapeutics to vaccines to drug delivery to diagnostics to cosmetics. Growth drivers such as improved drug delivery methods and enhanced manufacturing capabilities are fueling the surge in peptide use, while novel therapeutic applications owing to a peptide’s low toxicity and high potency are entering the pipeline at a rapid pace. The $6 billion (U.S.) worldwide peptide drug market alone is projected to grow to $10 billion by 2010. While the United States plays host to the largest share of the work in peptide research and development, significant
research networks exist in Europe and Asia as well.

With the rapidly growing list of applications, peptides are touching the lives of people in all walks of life and in all corners of the world. As people harness the power that peptides possess, this list will lengthen.

  • Oncology/cancer
  • Cardiovascular
  • Diabetes
  • Metabolic disease (e.g., diabetes)
  • Infection
  • Central nervous system
  • Dermatology

Yet with so much opportunity, so comes the challenges of navigating the wide array of sourcing options for quality peptides. The peptide supply chain is highly fragmented with many small players serving specific niches, so companies and organizations must turn to multiple providers to serve all peptide needs. Multiple questions arise throughout a project’s lifecycle: Which peptide provider should one trust with such a critical ingredient for success? Is location relevant? What is a fair price to pay? What is the right technology for the project?

The cost of poor quality is too great to place an uninformed or risky bet on peptide source. Projects – and entire organizations – can fail months or years down the road if peptide quality is compromised. A natural trend toward working with increasingly difficult sequences compounds the quality issue. Accordingly, companies are looking beyond their internal resources for peptide production.

The good news is that attractive solutions to these challenges do exist in the market today, and PharManufacturing is here as a key resource to help individuals along the way. The right choices and decisions will help position one for market success and for helping millions of people worldwide.

By Dave Robinson, CEO, New England Peptide, LLC

New England Peptide designs and manufactures custom peptides and polyclonal antibodies primarily for the therapeutic, vaccine, cosmetic and diagnostic markets. NEP collaborates with scientists at biopharma companies, academic institutions and government agencies around the world and has begun preparation to offer pharmaceutical-grade peptides to position the firm as a single source for all peptide needs.


"THANKS AGAIN for all the intellectual support that NEP has provided to us over the last year. My colleagues have been overwhelmingly impressed with the quality of service and level of thought that you have put into researching and thinking about our particular peptide and antibody production needs. The level of scholarship went well beyond what we expected from any peptide and antibody company, and was crucial in shaping our decisions. It has truly been a pleasure corresponding with you."
Cliff N. PhD - Lawrence Berkeley National Laboratory